Study Overview: This clinical trial is exploring whether adding a chemotherapy drug called docetaxel to usual treatments (hormonal therapy and apalutamide) is more effective for men with metastatic prostate cancer. Metastatic means the cancer has spread from the prostate to other parts of the body. Hormonal therapy, also known as androgen deprivation therapy (ADT), lowers male hormone levels to slow cancer growth. Apalutamide helps block these hormones. Docetaxel may stop cancer cells from growing and dividing.

• Duration: After treatment, patients are followed up every 6 months for up to 10 years.
• Treatment Visits: Docetaxel is given every 21 days for up to 6 doses, alongside regular imaging scans.
• Eligibility: Participants must have confirmed metastatic prostate cancer and meet specific health criteria.

This trial is important as it seeks to improve treatment outcomes and survival rates for men battling this type of cancer. Participants will be closely monitored to check for side effects and the effectiveness of the treatment.